In conclusion, although emerging evidence suggests that TMEM16A may serve as a valuable target in prostate cancer treatment, current research is limited by methodological discrepancies, a lack of mechanistic clarity, and an overreliance on in vitro studies. This evidence concerns the gene ANO1 and prostate carcinoma.